Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
Stocks · News reference
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a ---- Initial clinical data expected in 2027 --CAMBRIDGE,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo, PacBio and others posted double-digit gains.
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine announced the first patient dosing in its Phase 1/2 clinical trial of PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. The FDA granted Rare Pediatric Disease designation to PM577, and the company expects initial clinical data in 2027. PM577a is designed as a one-time curative therapy targeting the most prevalent Wilson disease-causing mutation in North America and Europe.
Prime Medicine Announces First Patient Dosed In Phase 1/2 Trial Of PM577a In Wilson Disease; Receives FDA Rare Pediatric Disease Designation